MaxCyte
MXCT | NASDAQ
$1.18
-$0.01 (-0.84%)
At close: Nov 16, 2026, 4:00 PM ET
$1.18
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:15 PM ET
-0.84%
(1D)No price chart data available for 1D timeframe.
Rating
48.8
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #312/1021 (Top 31%)
Key Statistics
Market Data
Market Cap $121.84M
1D Range
1.15 1.28
52W Range
0.68 1.76
Valuation (TTM)
PE -4.54
PB 0.81
EV/EBITDA -1.59
Valuation (NTM)
Forward PE N/A
Forward PEG 0.13
Price Target $4.00
Cash Flow
FCF Yield -17.7%
SBC Adj. FCF Yield -20.1%
SBC Impact -13.1%
Margins
Gross Margin 78.0%
Operating Margin -87.7%
FCF Margin -62.8%
Growth (CAGR)
Revenue 3Y | 5Y -3.3% |
1.3%
Dil EPS 3Y | 5Y 11.5% |
-5.7%
FCF 3Y | 5Y -0.7% |
1.2%
Returns
ROA -15.3%
ROE -17.2%
ROIC -17.9%
Financial Health
Net Cash
$101.28M
Current Ratio 7.83
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static elec...
Sector Healthcare
Industry Biotechnology
Employees 91
IPO Date Jul 29, 2021
Website www.maxcyte.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$0.05
Beat +35.48%
YoY:
+58.33% REV
$10.15M
Beat +37.35%
YoY:
+48.66%Next Earnings
Mar 16, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$4.00
Upside
+238.98%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove MXCT